StockNews.AI
FLGT
StockNews.AI
18 days

Fulgent Reports Second Quarter 2025 Financial Results

1. Fulgent reported a 16% year-over-year rise in core revenue. 2. The company faced a GAAP loss of $19 million in Q2 2025.

Earnings
+7.86%Current Return
VS
-1.64%S&P 500
$17.1808/01 07:12 AM EDTEvent Start
$18.5308/04 07:15 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bearish?

Despite revenue growth, the GAAP loss signals financial challenges, historically leading to price drops.

How important is it?

The significant GAAP loss affects investor sentiment, likely impacting FLGT's stock price.

Why Short Term?

Immediate investor reactions to losses can influence FLGT's price quickly, akin to past earnings reports.

Related Companies

QHGTNGENGALT
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Results: Total Revenue of $81.8 million Core Revenue1 grew 16% year-over-year to $81.7 million GAAP loss of $19.0 million, or ($0.62) per share Non-GAAP income of $2.1 million,.

Related News